8th Annual **HEREDITARY CANCER SYMPOSIUM** for Health Care Providers

In-Person and Virtual Format (Hybrid Environment) | April 4-5, 2025

Dan L. Duncan Building (CPB), Floor 8, 1155 Pressler Street, Houston, Texas 77030

Goal

The goal of this symposium is to provide health care professionals with knowledge and skills to recognize and treat hereditary cancers, resulting in the ability to improve patient care. Also, to recognize patients in need of a genetics evaluation.

Target Audience

This symposium should be of value to physicians, advanced practice providers, nurses, and oncology genetic counselors, physicians assistants, social workers, and students or trainees.

Education Methods

Lectures; Q&A Sessions; Case Studies; and Panel Discussions.



Accreditation

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy

Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 9.00 *AMA PRA Category 1 Credits*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center designates this live activity will award 9.00 Nursing Contact Hours.

Genetic Counselor Credits

This event will be submitted to the National Society of Genetic Counselors (NSGC) for approval of Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification. Approval for the requested CEUs and Contact Hours is currently pending.

Activity Directors

Banu Arun, MD, FASCO Susan Reilly, MS, CGC Andrew McKeon, MS, CGC



Program and Registration

For a complete program listing and registration information, please visit the conference webpage below.

MDAnderson.Cloud-Cme.com/Hereditary2025



Keynote Speaker Lori Minasian, MD, FACP

Dr. Lori Minasian, a medical oncologist, is the Deputy Director for the Division of Cancer Prevention at the NCI. She is a leader in the NCI clinical trials enterprise, first leading the NCI's Community Clinical Oncology Program (a communitybased clinical trials program) for over 15 years, and then supporting

a variety of the processes in the restructuring of the NCI's clinical trials programs. She has facilitated the development of numerous cancer prevention and symptom management clinical trials and has fostered the incorporation of patient reported outcomes in cancer clinical trials.

Dr. Minasian earned a Medical Degree from the George Washington University School of Medicine in Washington, D.C. She completed a fellowship in Medical Oncology at the Memorial Sloan-Kettering Cancer Center.



Making Cancer History®